KemPharm, Inc. to Present at Cowen and Company 34th Annual Health Care Conference - San Diego, California News Station - KFMB Channel 8 - cbs8.com

KemPharm, Inc. to Present at Cowen and Company 34th Annual Health Care Conference

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE KemPharm, Inc.

CORALVILLE, Iowa, Feb. 26, 2014 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that President and CEO, Travis Mickle, Ph.D., will present at the Cowen and Company 34th Annual Health Care Conference at the Boston Marriott Copley Place in Boston, MA.

Among the topics to be discussed, Dr. Mickle will provide an overview of KemPharm's development pipeline, including KP201, the company's lead clinical candidate for the treatment of acute moderate to moderately severe pain.  Composed of hydrocodone chemically bound to a ligand, KP201 offers unique physicochemical and pharmacological attributes that may deliver additional patient benefits, including reduced potential for abuse and reduction or elimination of opioid-induced constipation (OIC). 

Details of KemPharm's presentation are as follows:

Event:


Cowen and Company 34th Annual Health Care Conference

Date: 


Tuesday, March 4, 2014

Time: 


2:30 pm, EST

Location:


MIT Room, 3rd Floor - Boston Marriott Copley Place

About KemPharm

KemPharm is a biopharmaceutical company focused on the discovery and development of new chemical entities (NCEs) to treat serious medical conditions through its proprietary and broadly applicable Ligand Activated Therapy (LAT) approach.  The company utilizes its LAT technology to generate improved prodrug versions of FDA approved drugs in the high needs areas of pain, ADHD and other CNS diseases.  KemPharm's lead clinical candidate, KP201, is in development for the treatment of acute, moderate to moderately severe pain. Composed of hydrocodone chemically bound to a ligand, KP201 offers unique physicochemical and pharmacological attributes that may deliver additional patient benefits, including reduced potential for abuse and reduction or elimination of opioid-induced constipation (OIC). KemPharm's pipeline is also highlighted by KP511, its hydromorphone prodrug for pain, KP606, its oxycodone prodrug for pain, and KP415, a prodrug of methylphenidate for the treatment of ADHD.  For more information on KemPharm, please visit the company's website at www.kempharm.com.

For KemPharm, Inc:   

Media / Investor Contacts:

Christal Mickle

Jason Rando / Joshua Drumm, Ph.D.

319-665-2575

Tiberend Strategic Advisors, Inc.

info@kempharm.com 

212.827.0020


jrando@tiberend.com


jdrumm@tiberend.com

©2012 PR Newswire. All Rights Reserved.

  • Local NewsMore>>

  • Gang unit investigating stabbing Chicano Park

    Gang unit investigating stabbing Chicano Park

    Sunday, April 20 2014 1:36 PM EDT2014-04-20 17:36:23 GMT
    A 29-year-old man was undergoing treatment at a San Diego trauma center after he was stabbed in the torso at a park, a police sergeant said Sunday. 
    A 29-year-old man was undergoing treatment at a San Diego trauma center after he was stabbed in the torso at a park, a police sergeant said Sunday. 
  • Thousands pass through downtown checkpoint

    Thousands pass through downtown checkpoint

    Sunday, April 20 2014 1:29 PM EDT2014-04-20 17:29:39 GMT
    Nine motorists were arrested on suspicion of drunken driving and 13 vehicles were impounded during an overnight sobriety/driver's license checkpoint in the East Village section of downtown San Diego, a police officer said Sunday. 
    Nine motorists were arrested on suspicion of drunken driving and 13 vehicles were impounded during an overnight sobriety/driver's license checkpoint in the East Village section of downtown San Diego, a police officer said Sunday. 
  • Victim in I-8 chain reaction crash identified

    Victim in I-8 chain reaction crash identified

    Sunday, April 20 2014 1:26 PM EDT2014-04-20 17:26:33 GMT
    The 71-year-old man killed in a chain reaction crash on Interstate 8 in La Mesa late Friday night was publicly identified Sunday. 
    The 71-year-old man killed in a chain reaction crash on Interstate 8 in La Mesa late Friday night was publicly identified Sunday. 
Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and Midwest Television, Inc. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.